-
Agilent Q2 FY26 revenue $1.83B (+10% YoY), non-GAAP EPS $1.49 (+14%), raises FY26 guidance
Revenue $1.83B, +10% reported (+6.3% core); GAAP EPS $1.20 (+60%), non-GAAP EPS $1.49 (+14%).
-
Agilent Q1 FY2026 revenue $1.80B (+7% YoY), non-GAAP EPS $1.36 (+4%), raises FY guidance
Q1 revenue $1.80B, up 7% reported and 4.4% core YoY; GAAP EPS $1.07 (down 4%), non-GAAP EPS $1.36 (up 4%).
-
Agilent Q4 revenue $1.86B beats guidance; non-GAAP EPS $1.59 up 9%; initiates FY26 outlook $7.3-7.4B
Q4 revenue $1.86B, +9.4% reported/+7.2% core; GAAP EPS $1.53 (+25%); non-GAAP EPS $1.59 (+9%).
-
Agilent appoints Adam Elinoff as CFO effective Nov 17; $700k base salary plus equity
Adam S. Elinoff named CFO effective Nov 17, 2025, succeeding interim CFO Rodney Gonsalves.
-
Agilent beats Q3 with $1.74B revenue, raises FY2025 revenue outlook
Q3 revenue $1.74B, +10.1% reported / +6.1% core, above guidance; GAAP EPS $1.18 (+22%), Non-GAAP EPS $1.37 (+4%).
-
Agilent CFO Bob McMahon to resign effective July 31; Rodney Gonsalves named interim CFO
Bob McMahon, SVP & CFO, resigns effective July 31, 2025; departure for personal/family reasons, not related to accounting or operations.
-
Agilent Q2 revenue up 6% to $1.67B; Non-GAAP EPS $1.31, +7% YoY; raises FY outlook
Q2 revenue $1.67B (+6% reported, +5.3% core YoY); GAAP EPS $0.75 (-29%), Non-GAAP EPS $1.31 (+7%).
-
Agilent Q1 revenue $1.68B, non-GAAP EPS $1.31, beats expectations; maintains FY outlook
Revenue $1.68B, up 1.4% reported and 1.2% core YoY; GAAP EPS $1.11, down 6%; non-GAAP EPS $1.31, up 2%.
-
Agilent reorganizes into three business groups; names new presidents for LDG and AMG
New structure: Life Sciences & Diagnostics Markets Group (38% rev), Applied Markets Group (20%), Agilent CrossLab Group (42%).
-
Agilent Q4 revenue flat YoY; Non-GAAP EPS +6%; guides FY25 rev growth 4-5%
Q4 revenue $1.70B (flat YoY reported +0.8%, core -0.3%); GAAP EPS $1.22 (-25%), Non-GAAP EPS $1.46 (+6%).
-
Agilent closes $1.2B senior notes offering to finance BioVectra acquisition
Issued $600M 4.200% notes due 2027 and $600M 4.750% notes due 2034 at 99.866% and 99.638% of par, respectively.
-
Agilent prices $1.2B senior notes in two tranches: $600M 4.200% due 2027, $600M 4.750% due 2034
$600M 4.200% senior notes due 2027; $600M 4.750% senior notes due 2034.
-
Agilent Q3 revenue $1.58B beats guidance; GAAP EPS $0.97 (+155%); raises FY midpoint
Q3 revenue $1.58B (-5.6% reported, -4.4% core); GAAP EPS $0.97 (+155% YoY); non-GAAP EPS $1.32 (-8% YoY).
-
Agilent Q2 revenue down 8.4% YoY, cuts full-year outlook; authorizes $2B buyback
Q2 revenue $1.57B (-8.4% reported); GAAP EPS $1.05 (+3% YoY), non-GAAP EPS $1.22 (-4% YoY).
-
Padraig McDonnell becomes Agilent CEO as Mike McMullen retires May 1, 2024
Michael McMullen retired as President, CEO, and board member effective May 1, 2024; will serve as senior adviser through Oct. 31.
-
Agilent Q1 FY2024 revenue $1.66B (-5.6% YoY), EPS $1.18 GAAP/$1.29 non-GAAP; guides Q2 down
Revenue $1.66B, down 5.6% reported and 6.4% core YoY; GAAP EPS $1.18, non-GAAP EPS $1.29.
-
Agilent CEO Mike McMullen to retire May 1; Padraig McDonnell named CEO-elect and COO
Mike McMullen to retire as President and CEO effective May 1, 2024, then serve as senior advisor until Oct 31.
-
Agilent moves Cell Analysis Div. to D&G segment; recasts FY21-23 segment data
Cell Analysis Division moved from LSAG to Diagnostics & Genomics Group (DGG) effective Q1 FY24.
-
Agilent Q4 revenue $1.69B (-8.7% reported), non-GAAP EPS $1.38; FY24 guidance cautious
Q4 revenue $1.69B, down 8.7% reported and 9.7% core YoY; GAAP EPS $1.62 (+32%), non-GAAP EPS $1.38 (-10%).
-
Agilent names Philip Binns LSAG president after Jacob Thaysen departs
Jacob Thaysen resigned as SVP and president of Life Sciences and Applied Markets Group (LSAG), effective Sept. 5, 2023.
-
Agilent Q3 revenue down 2.7% YoY to $1.67B; GAAP EPS $0.38; lowers FY2023 guidance
Reported revenue $1.67B, down 2.7% YoY; core revenue down 2.3%.
-
Agilent Q2 revenue $1.72B (+6.8% reported, +9.5% core); guides FY revenue $6.93-7.03B, non-GAAP EPS $5.60-5.65
GAAP EPS $1.02, up 12% YoY; non-GAAP EPS $1.27, up 12% YoY.
-
Agilent Q1 revenue $1.76B (up 10% core); raises FY23 EPS guidance to $5.65-$5.70
GAAP EPS $1.19 (up 28% YoY); non-GAAP EPS $1.37 (up 13% YoY).
-
Agilent Q4 revenue $1.85B, non-GAAP EPS $1.53; guides FY2023 revenue $6.90-7.00B
Q4 revenue $1.85B, +11% reported (+17% core); GAAP EPS $1.23, non-GAAP EPS $1.53 (+26% YoY).
-
Agilent Q3 FY2022: EPS beat; guides FY rev $6.75-6.775B, non-GAAP EPS $5.06-5.08
Revenue $1.72B (+8% reported, +13% core); GAAP EPS $1.10 (+28% YoY); non-GAAP EPS $1.34 (+22% YoY).
-
Agilent Q2 revenue $1.61B (+7% core), non-GAAP EPS $1.13; raises FY core growth to 8-9%
GAAP net income $274M ($0.91 EPS) vs $216M ($0.70) YoY; non-GAAP $340M ($1.13 EPS) vs $299M ($0.97), up 16%.
-
Agilent enters $600M term loan to refinance 3.875% senior notes due 2023
Delayed draw term loan facility of $600M, maturing April 15, 2025.